United States President Donald Trump has signed an executive order aimed at lowering high drug prices in the country. The order instructs the Food and Drug Administration (FDA) to expedite the approval process for generic and biosimilar drugs, a move expected to increase competition and reduce consumer costs.

Additionally, the order empowers states to expand programs that import cheaper medicines from abroad. This initiative seeks to close the pricing gap between the United States and other developed countries, where prescription medications often cost significantly less.

The executive action also revises elements of former President Joe Biden’s Inflation Reduction Act. Specifically, it unifies price negotiations for both pills and injectable medications under the Medicare system, streamlining the process and potentially amplifying Medicare's negotiating power to achieve lower prices for millions of beneficiaries.

White House officials stated that the combination of these measures is intended to foster a more competitive pharmaceutical market, reduce monopolistic pricing, and provide immediate relief to American consumers struggling with high prescription costs.

In parallel with the executive order, the White House launched a national security investigation into foreign drug imports. The investigation aims to assess the potential risks associated with overseas pharmaceutical sourcing and ensure the safety and reliability of imported medicines.

The simultaneous policy and security efforts reflect a comprehensive approach by the Trump administration to reform the pharmaceutical sector. By encouraging domestic competition, leveraging global markets, and addressing systemic inefficiencies, the administration hopes to make significant strides toward more affordable and accessible healthcare for all Americans.